TY - JOUR
T1 - No association between GRM3 and Japanese methamphetamine induced psychosis
AU - Tsunoka, Tomoko
AU - Kishi, Taro
AU - Ikeda, Masashi
AU - Kitajima, Tsuyoshi
AU - Yamanouchi, Yoshio
AU - Kinoshita, Yoko
AU - Kawashima, Kunihiro
AU - Okochi, Tomo
AU - Okumura, Takenori
AU - Inada, Toshiya
AU - Ujike, Hiroshi
AU - Yamada, Mitsuhiko
AU - Uchimura, Naohisa
AU - Sora, Ichiro
AU - Iyo, Masaomi
AU - Ozaki, Norio
AU - Iwata, Nakao
PY - 2011
Y1 - 2011
N2 - Several investigations have suggested that abnormalities in glutamate neural transmission play a role in the pathophysiology of psychiatric disorders, including schizophrenia. The metabotropic glutamate 3 receptor (mGluR3) gene was reported to be associated with schizophrenia, and paranoid type schizophrenia has symptoms that are similar to those of methamphetamine-induced psychosis. This suggests that mGluR3 gene (GRM3) is a good candidate gene for the pathogenesis of methamphetamine-induced psychosis. To evaluate the association between GRM3 and methamphetamine-induced psychosis, we conducted a case-control study of Japanese samples (181 methamphetamine-induced psychosis and 232 controls). Methods: We selected one functional SNP (rs6465084), reported to be associated with prefrontal brain functioning, for an association analysis. Written informed consent was obtained from each subject. This study was approved by the ethics committees at Fujita Health University, Nagoya University Graduate School of Medicine and each participating member of the Institute of the Japanese Genetics Initiative for Drug Abuse (JGIDA). Results: We did not detect an association between rs6465084 in GRM3 and Japanese methamphetamine-induced psychosis. Conclusion: Our findings suggest that rs6465084 in GRM3 does not play a major role in the pathophysiology of methamphetamine-induced psychosis in the Japanese population. However, because we did not perform an association analysis based on linkage disequilibrium (LD) or a mutation scan of GRM3, a replication study using a larger sample and based on LD may be required for conclusive results.
AB - Several investigations have suggested that abnormalities in glutamate neural transmission play a role in the pathophysiology of psychiatric disorders, including schizophrenia. The metabotropic glutamate 3 receptor (mGluR3) gene was reported to be associated with schizophrenia, and paranoid type schizophrenia has symptoms that are similar to those of methamphetamine-induced psychosis. This suggests that mGluR3 gene (GRM3) is a good candidate gene for the pathogenesis of methamphetamine-induced psychosis. To evaluate the association between GRM3 and methamphetamine-induced psychosis, we conducted a case-control study of Japanese samples (181 methamphetamine-induced psychosis and 232 controls). Methods: We selected one functional SNP (rs6465084), reported to be associated with prefrontal brain functioning, for an association analysis. Written informed consent was obtained from each subject. This study was approved by the ethics committees at Fujita Health University, Nagoya University Graduate School of Medicine and each participating member of the Institute of the Japanese Genetics Initiative for Drug Abuse (JGIDA). Results: We did not detect an association between rs6465084 in GRM3 and Japanese methamphetamine-induced psychosis. Conclusion: Our findings suggest that rs6465084 in GRM3 does not play a major role in the pathophysiology of methamphetamine-induced psychosis in the Japanese population. However, because we did not perform an association analysis based on linkage disequilibrium (LD) or a mutation scan of GRM3, a replication study using a larger sample and based on LD may be required for conclusive results.
KW - Case-control study
KW - GRM3
KW - Methamphetamine-induced psychosis
UR - https://www.scopus.com/pages/publications/79953039960
UR - https://www.scopus.com/pages/publications/79953039960#tab=citedBy
U2 - 10.2174/157015911795017001
DO - 10.2174/157015911795017001
M3 - Article
C2 - 21886583
AN - SCOPUS:79953039960
SN - 1570-159X
VL - 9
SP - 160
EP - 162
JO - Current Neuropharmacology
JF - Current Neuropharmacology
IS - 1
ER -